Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > So far so good

<< Previous

Bullboard Posts

Next >>

Comment by jfm1330on Apr 08, 2021 11:46am

87 Views

Post# 32956843

RE:RE:So far so good

Cannot believe they would select a patient without knowing his cancer has overexpression of sortilin. That being said, what Dr. Shah is saying, that it can be used on any solid tumor is scary, because it's not the case. The key of the whole thing is sortilin overexpression. Without that, it will not work as planned.

Wino115 wrote: This is the first time we've heard Prostate Cancer... I'm not sure what level of Sortilin is expressed for that. Or is that what they've put under the more generic "gynecological" cancers? Hope it works, but not the primary kind of tumor we're looking for.

scarlet1967 wrote: https://www.abc27.com/news/local/gettysburg-doctor-patient-first-in-the-world-to-try-new-cancer-treatment/amp/